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a b s t r a c t
We identiﬁed thirteen patients with desmoplastic ﬁbroma of bone treated at our institute over a 30 year
period. The patients had a mean age of 25.9 years; eight were female. The incidence of desmoplastic
ﬁbroma of bone in all patients with benign bone tumours in our population is 0.003%. Surgical treatment
ranged from primary amputation to intra-lesional curettage. The incidence of local recurrence was 15.4%.
All cases of local recurrence after curettage or marginal excision demonstrated soft-tissue extension of
their tumours on initial presentation suggesting that extra-osseous extension requires more radical
surgery to control the disease.
This study presents the largest single centre series of desmoplastic ﬁbroma of bone with a mean
follow-up time of 8 years. We recommend wide surgical excision, particularly if the lesion can be
resected without signiﬁcant loss of function, as the treatment modality of choice with the lowest rate of
recurrence. Patients undergoing intra-lesional or marginal resection need to be advised of the possibility
of local recurrence and the need for long-term surveillance.
& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Desmoplastic ﬁbroma (DF) is a rare, locally aggressive benign
bone tumour with a reported incidence of 0.11% of all primary
bone tumours [1,2]. It was initially described by Jaffe [3] in 1958
who highlighted the histological resemblance to aggressive ﬁbro-
matosis (desmoid tumour). Numerous authors have subsequently
attempted to clarify the histological criteria and, in 2013, the WHO
described the microscopic appearance of desmoplastic ﬁbroma as
being composed of slender, spindle to stellate cells with minimal
cytological atypia and abundant collagenous matrix [4]. Because of
the inﬁltrative pattern of growth, desmoplastic ﬁbroma was
considered by some to be the osseous counterpart of extra-
abdominal desmoid tumour [5], however, a recent study revealed
that there were no mutations in exon 3 of CTNNB1, encoding for
B-catenin, thus genetically distinguishing desmoplastic ﬁbromas
of bone from desmoid-type ﬁbromatosis [6]. Local recurrence rates
are between 37% and 72% [7–9] following operative intervention.
Patients present typically with pain and swelling of the affected
area. Plain radiographs reveal a trabeculated, lucent, expansile
lesion often with lobulated margins [10]. Cortical thinning with
breakthrough and a soft-tissue mass may also be seen [7].
Establishing a diagnosis is difﬁcult by imaging studies alone [2]
as many tumours resemble desmoplastic ﬁbroma. The differential
diagnosis includes benign lesions, such as ﬁbrous dysplasia, simple
bone cyst, aneurysmal bone cyst, non-ossifying ﬁbroma, eosino-
philic granuloma and chondromyxoﬁbroma [2,7]. If cortical
destruction and a soft tissue mass is noted, desmoplastic ﬁbroma
of bone may resemble more sinister pathology, such as ﬁbrosar-
coma, intra-osseous osteosarcoma and metastases [2,7].
To date, small numbers of case reports and case series have
been published regarding desmoplastic ﬁbroma. The aim of this
paper is to present the largest single-centre series of desmoplastic
ﬁbroma of bone with a view to outline a management strategy and
to discuss the criteria associated with local recurrence.
2. Methods
We conducted a retrospective search of a prospective tumour
database to identify all patients treated at our unit with a
diagnosis of desmoplastic ﬁbroma of bone. The diagnosis was
conﬁrmed following a multidisciplinary review of the patient's
clinical history, pertinent radiological imaging and histological
ﬁndings. Patient demographics were recorded along with the site
of their disease and management, with local recurrence and the
need for revision surgery being deﬁned as end-points.
2.1. Statistical analysis
Simple summary statistics were collated using SPSS v 18.0
software (IBM Corp., Armonk, New York). Categorical data was
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compared using the chi-squared test or Fisher's exact test, with an
alpha value of 0.05 considered statistically signiﬁcant.
3. Results
A search of our database, which holds prospectively gathered
data on over 30,000 patients including 4692 benign bone tumours,
identiﬁed 13 patients with desmoplastic ﬁbroma of bone, giving
an incidence of 0.003% in our population. There were 8 females
(61.5%) and 5 males (38.5%). Mean age at presentation with
symptoms was 25.9 years (range 5–50 years). Skeletal distribution
of the lesions is shown in Fig. 1.
All patients had been referred to our unit with suspicious plain
radiographs following a history of pain/swelling of the affected
body area and subsequently underwent magnetic resonance
imaging and needle biopsy to conﬁrm the diagnosis (Table 1).
Two patients (cases 1 and 7) declined any treatment following
conﬁrmation of their diagnosis and were discharged with advice
to return if concerned.
6 patients underwent intra-lesional curettage. Of those patients, 2
(cases 8 and 13) developed rapid local recurrence at 9 and 7 months
post-curettage respectively. Both cases had extra-osseous soft-tissue
components to their tumours at initial curettage. Case 8 had
intractable pain associated with an extensive local recurrence that
necessitated a below knee amputation to control their disease 24
months after initial curettage. Case 13 presented with a distal radial
desmoplastic ﬁbroma that was initially treated with curettage alone
because of the difﬁculty of resection and reconstruction. However,
rapid local recurrence necessitated further curettage with marginal
excision of the soft-tissue component. 12 months post-revision
surgery, he has normal upper limb function with no symptoms of
recurrence.
3 patients underwent a marginal excision. There have been no
recurrent tumours reported with a median time since operation of
12.1 years (range 9.7–15.3).
One patient (case 6) underwent wide excision of their lesion,
with endo-prosthetic replacement (EPR) of their proximal tibia. No
local recurrence has been detected 15.1 years following their index
operation, although revision EPR was required for aseptic compo-
nent loosening of the tibial component after 11.3 years.
1 patient (case 4) elected to undergo a below knee amputation
as limb salvage was not deemed possible due to the extensive intra
and extra-osseous nature of their distal tibial lesion.
In total, local recurrence occurred in 2 (15.4%) patients in our
series. There was a statistically signiﬁcant association between
local recurrence and the presence of an extra-osseous soft-tissue
component (po0.023).
Fig. 1. Skeletal distribution of disease.
Table 1
Patient demographics, treatment and survival.
Case
no.
Sex Age Site Clinical
presentation
Treatment 1 Margins Time to recurrence
(months)
Symptom free period
(months)
1 F 5 Ischium Pain Nil – – –
2 M 44 Radial diaphysis Pain, swelling Excision Marginal – 116
3 F 35 Proximal ﬁbula Pain, swelling Excision Marginal – 145
4 F 22 Extensive lesion distal tibia Pain BKA Amputation – 158
5 M 15 Radius Swelling Excisionþﬁbula
graft
Marginal – 183
6 M 24 Extensive lesion proximal
tibia
Pain EPR proximal tibia Wide/
complete
– 181
7 F 29 Iliac wing Pain Nil – – –
8 F 12 Calcaneum Pain, swelling Curettage Intralesional 9 9
9 F 18 1st metacarpal Swelling Curettage Intralesional – 66
10 F 50 Talus Pain, swelling Curettage Intralesional – 59
11 F 48 2nd metatarsal Pain Curettage Intralesional – 23
12 M 25 Talus Pain Curettage Intralesional – 14
13 M 10 Distal radius Pain, swelling Curettage Intralesional 7 7
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4. Discussion
The aim of this study was to use a large database of patients
with benign orthopaedic tumours in order to outline a manage-
ment strategy for patients diagnosed with desmoplastic ﬁbroma of
bone and to discuss the criteria associated with local recurrence.
Of the 4692 patients treated at our institute with a benign bone
tumour over 30 years we found 13 had a diagnosis of desmoplastic
ﬁbroma of bone. Our unit has treated 1440 patients with osteo-
sarcoma during the same period as we treated these patients with
desmoplastic ﬁbroma and it is known that the incidence of
osteosarcoma is 2.5/million population per year [11]. Thus, the
incidence of desmoplastic ﬁbroma of bone is approximately
13/1440 of osteosarcoma i.e. a ﬁgure of 0.009/million population
per year or approximately 1% of the reported incidence of
osteosarcoma. This converts to an expected 2.5 cases of desmo-
plastic ﬁbroma of bone for every 100 million population.
Local recurrence occurred in 15.4% of patients in our series and
was statistically signiﬁcantly linked to desmoplastic ﬁbromas with
associated soft-tissue components. This suggests that desmoplas-
tic ﬁbromas with extra-osseous extension are at the extreme end
of the locally aggressive spectrum and, therefore, require more
radical surgery than curettage or marginal excision.
The cross-sectional imaging features of desmoplastic ﬁbroma
have been described [2,9,12] as an osteolytic lesion with destruc-
tion of cortical bone, marginal sclerosis and pseudotrabeculation.
The tumour shows low signal intensity on T1-weighted images
with signal enhancement after the administration of contrast [2,9].
Cortical breakthrough was present in 23.1% of patients in our
series, which is comparable to the study by Crim [13] who, after
evaluating the radiographical features of desmoplastic ﬁbroma in
83 published case reports, demonstrated cortical breakthrough in
29% of patients. We recommend magnetic resonance imaging
(MRI) of the affected area to accurately delineate the extent of
the tumour and it's relation to surrounding anatomical structures.
Computed topography (CT) can supplement MRI and provide a
more precise picture of the boney architecture so as to guide
surgical management.
The diagnosis is very difﬁcult on radiographical imaging alone
as many tumours have similar radiological appearances to desmo-
plastic ﬁbroma [2,7]. Biopsy is the gold standard method of
determining the exact nature of any bony lesion as it provides a
tissue diagnosis. The biopsy ideally should be performed at a
reference bone tumour centre under the auspices of a fully
accredited multi-disciplinary team. A unit familiar with the diag-
nosis of such rare pathology can, therefore, evaluate the clinical,
radiological and histological features of this difﬁcult disease so as
to plan management.
Radiotherapy has been reported to be a therapeutic option in the
treatment of desmoplastic ﬁbroma. Sanﬁlippo et al. [14] used 60 Gy
in 30 fractions to treat desmoplastic ﬁbroma of the ilium, while Nag
et al. [15] treated one patient with 45 Gy in 25 fractions for
desmoplastic ﬁbroma to the distal femur. We have no experience
in the use of adjuvant radiotherapy in the management of desmo-
plastic ﬁbroma of bone at our institute.
In conclusion, desmoplastic ﬁbroma is a rare, locally aggressive,
benign neoplasm of bone. The diagnosis and management is often
difﬁcult and requires a combined specialty approach. Our study
highlights that extra-osseous tumour growth appears to be a poor
prognostic sign. Wide resection is the ideal treatment of choice
particularly if the lesion is located in a region where limb salvage
surgery can provide restoration of function. Curettage or marginal
resection can be used if en bloc resection would result in
signiﬁcant post-operative morbidity and loss of function. However,
patients should be advised about the need for serial clinical and
radiological follow-up to detect any local recurrence as early as
possible, particularly if their tumours have soft-tissue compo-
nents, with amputation always being available in the armamen-
tarium for recalcitrant disease.
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